Using both tobacco and cannabis during pregnancy is more common in minoritized groups and can make quitting smoking in pregnancy and remaining smoke free postpartum difficult. Investigators will test an intervention to address prenatal depressive symptoms to encourage people to quit tobacco and cannabis during pregnancy and stay quit postpartum.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
Participants will meet one-on-one with a study interventionist over the course of 6 prenatal treatment sessions and 3 postpartum maintenance sessions. Sessions will include education and discussion on self-monitoring of targets/ problem identification, psychoeducation, behavioral activation, cognitive restructuring, and mindfulness skills.
Bellefield Towers
Pittsburgh, Pennsylvania, United States
Attendance
Rate of attendance will be measured by proportion of sessions attended to total available sessions.
Time frame: From enrollment to 3 months postpartum
Completion of Intervention-Related Procedures
Participant will complete activities designed to help them self-monitor their smoking-related behaviors during and between scheduled treatment sessions. Completion of activities will be measured by the proportion of completed activities to the total number of assigned activities.
Time frame: From enrollment to 3 months postpartum
Acceptability of the Intervention
Participants' acceptance of the intervention will be measured using the Acceptability of Intervention Measure (AIM) at the 3-month postpartum assessment. This is a 4-item questionnaire with a scale range of 4-20, with a higher score indicating greater acceptance.
Time frame: From enrollment to 3 months postpartum
Abstinence from Tobacco Products
Abstinence from tobacco products will be measured by proportion of the participants who self-report no use of tobacco and by calculating the proportion of participants with negative urine screens for cotinine at the 3-month postpartum assessment.
Time frame: Baseline assessment to 3 months postpartum
Abstinence from Cannabis Products
Abstinence from cannabis products will be measured by proportion of the participants who self-report no use of cannabis and by calculating the proportion of participants with negative urine screens for THC at the 3-month postpartum assessment.
Time frame: Baseline assessment to 3 months postpartum.
Depressive Symptoms from Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in depressive symptoms will be measured through self-report Edinburgh Postnatal Depression Scale (EPDS) at baseline assessment, pre-delivery treatment session, and 1 and 3 months postpartum assessments. The scale range is 0-30, with a higher score indicating higher depression.
Time frame: Baseline assessment to 3 months postpartum
Change in Tobacco Use from Baseline
Change in tobacco use from baseline will be measured through a self-reported smoking questionnaire given at baseline assessment, pre-delivery treatment session, and 1 and 3 months postpartum assessments.
Time frame: Baseline assessment to 3 months postpartum
Change in Cannabis Use from Baseline
Change in cannabis use from baseline will be measured through a self-reported smoking questionnaire given at baseline assessment, pre-delivery treatment session, and 1 and 3 months postpartum assessments.
Time frame: Baseline assessment to 3 months postpartum